PropThink: ELN Under Pressure On ECTRIMS Meeting & Valuation

[ACN Newswire] – By David MoskowitzWith Biogen-Idec’s (NASDAQ:BIIB) new multiple sclerosis (MS) treatment, BG-12, approaching a decision by the FDA (PDUFA date December 28th), enthusiasm in the medical community is building … more

View todays social media effects on ELN

View the latest stocks trending across Twitter. Click to view dashboard